Abstract Number: 1567 • 2013 ACR/ARHP Annual Meeting
Desensitization To Trimethoprim/Sulfamethoxazole In Systemic Lupus Erythematosus Patients : A Retrospective Cohort Study
Background/Purpose: A high incidence of trimethoprin-sulfamethoxazole (TMP/SMX) hypersensitivity is reported in patients with systemic lupus erythematosus (SLE), and reactions are often severe. Desensitization protocol is…Abstract Number: 1568 • 2013 ACR/ARHP Annual Meeting
A Comparative Study For High Prevalence Of A Positive Family History Of Systemic LUPUS Erythematosus In Juvenile-Onset Systemic LUPUS Erythematosus Versus Adult-Onset Disease
Background/Purpose: The pathogenesis of SLE is complex and poorly understood. Infectious triggers, immunological abnormalities, environmental factors and genetic background play a combined role in disease…Abstract Number: 1569 • 2013 ACR/ARHP Annual Meeting
The Accuracy Of The ICD-9 Code 710.0 To Identify a Cohort Of SLE Patients From The Electronic Medical Record
Background/Purpose: The electronic medical record (EMR) is increasingly used as a primary source of retrospective research data from large 'virtual cohorts' of patients. The accuracy…Abstract Number: 1570 • 2013 ACR/ARHP Annual Meeting
Maintenance Therapy With Taclorimus and Mizoribine Pulse In SLE
Background/Purpose: It was reported in 2008 that multitarget therapy, consisting of taclorimus (TAC), mycophenolate mofetil (MMF) and glucocorticoid, is effictive and safe in induction therapy…Abstract Number: 1571 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Tacrolimus Combination Therapy During The Maintenance Phase Of Systemic Lupus Erythematosus
Background/Purpose: In Japan, a placebo-controlled clinical trial was undertaken to investigate the efficacy and safety of tacrolimus (TAC) for lupus nephritis. Based on the results…Abstract Number: 1572 • 2013 ACR/ARHP Annual Meeting
High Type I Interferon In Systemic Lupus Erythematosus Plasma Predicts Future Renal Disease
Background/Purpose: Type I interferon (IFN-I) is elevated in many patients with SLE and is associated with more severe disease. However, the relationship between elevated levels…Abstract Number: 1573 • 2013 ACR/ARHP Annual Meeting
Longer Duration Of B Cell Depletion In Patients With Systemic Lupus Erythematosus Is Associated With a Better Outcome
Background/Purpose: We were alerted to the possibility of very long term B cell depletion (BCD) in Systemic Lupus Erythematosus (SLE) by a patient treated with…Abstract Number: 1574 • 2013 ACR/ARHP Annual Meeting
Favorable Clinical Response To Belimumab At Three Months
Background/Purpose: Belimumab (Benlysta) is a human monoclonal antibody that inhibits soluble B-Lymphocyte Stimulator and improves SLE disease activity. This study was initiated to evaluate the…Abstract Number: 1575 • 2013 ACR/ARHP Annual Meeting
Identification Of Novel Distinct Autoantigen Clusters Reflecting The Heterogeneity Of Systemic Lupus Erythematosus
Background/Purpose: Diagnosis of systemic lupus erythematosus (SLE) is based on a combination of clinical findings and laboratory evidence such as anti-nuclear autoantibodies (ANA), anti-Smith and…Abstract Number: 1576 • 2013 ACR/ARHP Annual Meeting
Type I Interferon-Mediated Skewing Of The Serotonin Synthesis In Systemic Lupus Erythematosus Is Associated To Cardiovascular Disease
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease characterized by increased expression of type I interferons (IFNs). Indoleamine 2,3-dioxygenase (IDO), a type I…Abstract Number: 1577 • 2013 ACR/ARHP Annual Meeting
Comparison Of Clinical and Serological Manifestations Among Juvenile-, Adult-, and Late-Onset Systemic Lupus Erythematosus Patients In Korea
Background/Purpose: Up to 30‑40% of patients with systemic lupus erythematosus (SLE) experience their onset prior to adulthood or at over 50 years of age. Patients…Abstract Number: 1578 • 2013 ACR/ARHP Annual Meeting
Decreased Sensitivity Of a Commercial Anti-dsDNA Assay In Patients With Moderately To Severely Active Systemic Lupus Erythematosus
Background/Purpose: Anti-dsDNA autoantibodies are highly specific for SLE. Anti-dsDNA positivity is an important eligibility criterion in many SLE studies, and decreases in anti-dsDNA levels are…Abstract Number: 1579 • 2013 ACR/ARHP Annual Meeting
Novel Risk Factors For Thrombotic Thrombocytopenic Purpura In Systemic Lupus Erythematosus patients
Background/Purpose: Thrombotic thrombocytopenic purpura (TTP) is an uncommon disease characterized by thrombocytopenia and microangiopathic hemolytic anemia and, in some cases, fever, neurologic and/or renal abnormalities.…Abstract Number: 1580 • 2013 ACR/ARHP Annual Meeting
Drug-Resistant Bloodstream Infections In Systemic Lupus Erythematosus Patients: A Clinical Perspective
Background/Purpose: Infections are an important cause of mortality and morbidity in Systemic Lupus Erythematosus (SLE) patients. Different risk factors have been described for the development…Abstract Number: 1581 • 2013 ACR/ARHP Annual Meeting
Lipid Lowering Medication Use Is Associated With Reduced Muscle Strength In Systemic Lupus Erythematosus
Background/Purpose: Premature atherosclerotic coronary artery disease is a major source of morbidity for women with systemic lupus erythematosus (SLE). Lipid lowering medications (LLM) are among…
ACR Meeting Abstracts